IN2012DN02675A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02675A
IN2012DN02675A IN2675DEN2012A IN2012DN02675A IN 2012DN02675 A IN2012DN02675 A IN 2012DN02675A IN 2675DEN2012 A IN2675DEN2012 A IN 2675DEN2012A IN 2012DN02675 A IN2012DN02675 A IN 2012DN02675A
Authority
IN
India
Prior art keywords
met
cess
indazol
dicyano
pro
Prior art date
Application number
Other languages
English (en)
Inventor
Michels Martin
Follmann Markus
Vakalopoulos Alexandros
Zimmermann Katja
Teusch Nicole
Lobell Mario
Bierer Donald
Engel Karen
Kissel Maria
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of IN2012DN02675A publication Critical patent/IN2012DN02675A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN2675DEN2012 2009-10-06 2010-10-01 IN2012DN02675A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172304 2009-10-06
PCT/EP2010/064648 WO2011042368A1 (en) 2009-10-06 2010-10-01 Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2012DN02675A true IN2012DN02675A (enExample) 2015-09-04

Family

ID=43357944

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2675DEN2012 IN2012DN02675A (enExample) 2009-10-06 2010-10-01

Country Status (27)

Country Link
US (1) US9422263B2 (enExample)
EP (1) EP2485726B1 (enExample)
JP (1) JP5753175B2 (enExample)
KR (1) KR20120091005A (enExample)
CN (1) CN102573838B (enExample)
AR (1) AR078486A1 (enExample)
AU (1) AU2010305550A1 (enExample)
BR (1) BR112012006842A2 (enExample)
CA (1) CA2773676C (enExample)
CL (1) CL2012000753A1 (enExample)
CR (1) CR20120150A (enExample)
CU (1) CU20120051A7 (enExample)
DO (1) DOP2012000085A (enExample)
EC (1) ECSP12011748A (enExample)
ES (1) ES2458117T3 (enExample)
IL (1) IL218415A0 (enExample)
IN (1) IN2012DN02675A (enExample)
MX (1) MX2012003603A (enExample)
NZ (1) NZ599006A (enExample)
PE (1) PE20121392A1 (enExample)
PH (1) PH12012500640A1 (enExample)
RU (1) RU2012111695A (enExample)
SG (1) SG178990A1 (enExample)
TW (1) TW201124396A (enExample)
UY (1) UY32922A (enExample)
WO (1) WO2011042368A1 (enExample)
ZA (1) ZA201201524B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0650179Y2 (ja) 1989-06-01 1994-12-21 株式会社プラコー ブロー成形機用のダイヘッド
JPH0756186Y2 (ja) 1989-07-24 1995-12-25 株式会社日本製鋼所 パリソンの押出成形装置
JP2781376B2 (ja) 1996-06-17 1998-07-30 エクセル株式会社 中空成形品
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
IL285421B1 (en) 2019-02-11 2025-10-01 Merck Patent Gmbh History of indazolyl-isoxazoles, their preparation and pharmaceutical preparations containing them

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635977A (en) 1969-11-03 1972-01-18 American Cyanamid Co Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil
ATE126207T1 (de) 1989-01-26 1995-08-15 Bayer Ag Optisch aktive (meth)acrylsäure-derivate, ihre herstellung, ihre polymerisation zu optisch aktiven polymeren und deren verwendung.
DE19546136A1 (de) 1995-12-11 1997-06-12 Bayer Ag Chirale stationäre Phasen für die chromatographische Trennung von optischen Isomeren
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
RU2007126551A (ru) 2004-12-13 2009-01-20 Айрм Ллк (Bm) Соединения и композиции, как модуляторы стероидных рецепторов и активности кальциевых каналов
WO2006074419A2 (en) 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
CA2595130A1 (en) * 2005-01-19 2006-07-27 Paul J. Coleman Mitotic kinesin inhibitors
CL2007003609A1 (es) * 2006-12-14 2008-07-25 Bayer Schering Pharma Ag Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion

Also Published As

Publication number Publication date
CA2773676C (en) 2017-07-04
CL2012000753A1 (es) 2012-09-14
DOP2012000085A (es) 2012-07-15
ECSP12011748A (es) 2012-05-30
AR078486A1 (es) 2011-11-09
KR20120091005A (ko) 2012-08-17
JP2013506699A (ja) 2013-02-28
UY32922A (es) 2011-04-29
PE20121392A1 (es) 2012-10-14
BR112012006842A2 (pt) 2016-06-07
NZ599006A (en) 2013-11-29
CU20120051A7 (es) 2012-06-29
AU2010305550A1 (en) 2012-03-29
TW201124396A (en) 2011-07-16
US20120264785A1 (en) 2012-10-18
CR20120150A (es) 2012-08-03
CN102573838A (zh) 2012-07-11
WO2011042368A1 (en) 2011-04-14
ZA201201524B (en) 2013-05-29
ES2458117T3 (es) 2014-04-30
EP2485726B1 (en) 2014-03-12
SG178990A1 (en) 2012-04-27
US9422263B2 (en) 2016-08-23
IL218415A0 (en) 2012-04-30
HK1172835A1 (en) 2013-05-03
JP5753175B2 (ja) 2015-07-22
CA2773676A1 (en) 2011-04-14
PH12012500640A1 (en) 2012-11-12
EP2485726A1 (en) 2012-08-15
RU2012111695A (ru) 2013-10-10
MX2012003603A (es) 2012-04-20
CN102573838B (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
GEP20146101B (en) Pyridine and pyrazine derivatives as protein kinase modulators
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
MX2009012623A (es) Moduladores de cinasa heterociclicos.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
EA201270480A1 (ru) Новые соединения
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
ATE523510T1 (de) Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
IN2012DN02471A (enExample)
CU20110215A7 (es) Piperidinas sustituidas
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
IN2012DN02675A (enExample)
WO2010129048A3 (en) Therapeutic compounds
CO6470822A2 (es) Piperidinas susituidas
ATE540042T1 (de) Annelierte 4-(indazolyl)-1,4- dihydropyridinderivate als c-met-mediatoren